Roche announces EMBARK trial in Duchenne muscular dystrophy did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints Roche (SIX: RO, ROG; OTCQX:…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy Novartis today announced positive topline results from the interim analysis…
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate Merck, a leading science and technology company, today announced a strategic collaboration with…
Phase III RUBY trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer GSK plc today announced positive headline results…
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna’s…
Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023…
FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion
FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA)…
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK
GSK launches £6m programme to boost STEM career progression for young people from under-represented groups in the UK GSK plc today announced the launch of a £6m, 10-year STEM equity…
Moderna Named a Top Employer by Science for Ninth Consecutive Year
Moderna Named a Top Employer by Science for Ninth Consecutive Year Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry…
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces…
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy,…
Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer Positive results from the primary analysis of the DUO-E…